Characteristic | Patients with EM (n = 416) | Patients with CM (n = 587) | Patients with MO (n = 220) | Patients with MDD (n = 134) | Patients with GAD (n = 120) | Prior CGRP exposure (n = 98) |
---|---|---|---|---|---|---|
Age, years, mean (SD) | 38.5 (12.2) | 40.5 (12.5) | 40.7 (12.4) | 40.1 (10.6) | 39.0 (11.7) | 43.0 (12.2) |
Sex, n (%) | ||||||
 Female | 301 (72.4) | 459 (78.2) | 155 (70.5) | 110 (82.1) | 99 (82.5) | 77 (78.6) |
 Male | 115 (27.6) | 126 (21.5) | 65 (29.5) | 24 (17.9) | 21 (17.5) | 21 (21.4) |
 Other | 0 (0.0) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Race, n (%) | ||||||
 White | 317 (76.2) | 465 (79.2) | 158 (71.8) | 112 (83.6) | 99 (82.5) | 78 (79.6) |
 Black or African American | 59 (14.2) | 78 (13.3) | 42 (19.1) | 14 (10.4) | 11 (9.2) | 11 (11.2) |
 Asian | 26 (6.3) | 30 (5.1) | 10 (4.5) | 5 (3.7) | 5 (4.2) | 1 (1.0) |
 Native American or American Indian | 6 (1.4) | 1 (0.2) | 2 (0.9) | 0 (0.0) | 0 (0.0) | 1 (1.0) |
 Other | 8 (1.9) | 12 (2.0) | 7 (3.2) | 3 (2.2) | 5 (4.2) | 6 (6.1) |
 Unknown | 0 (0.0) | 1 (0.2) | 1 (0.5) | 0 (0.0) | 0 (0.0) | 1 (1.0) |
Duration of follow-up, months, mean (SD) | 7.1 (4.4) | 7.0 (4.5) | 7.1 (3.7) | 7.3 (4.4) | 7.6 (4.5) | 7.2 (4.7) |
Baseline MMD, mean (SD) | 10.0 (5.1) | 14.7 (6.5) | 13.4 (6.7) | 14.5 (6.1) | 14.3 (6.3) | 13.1 (6.2) |
Baseline MHD, mean (SD) | 10.7 (6.1) | 16.4 (8.3) | 15.8 (8.8) | 17.5 (8.0) | 16.7 (8.3) | 14.6 (7.9) |
Prior preventive treatment failures, n (%) | ||||||
 0 | 34 (8.2) | 26 (4.4) | 1 (0.5) | 4 (3.0) | 3 (2.5) | 1 (1.0) |
 1 | 54 (13.0) | 57 (9.7) | 12 (5.5) | 11 (8.2) | 9 (7.5) | 9 (9.2) |
 2 | 120 (28.8) | 126 (21.5) | 36 (16.4) | 20 (14.9) | 18 (15.0) | 17 (17.3) |
 3 | 105 (25.2) | 177 (30.2) | 62 (28.2) | 42 (31.3) | 39 (32.5) | 17 (17.3) |
 4 | 52 (12.5) | 109 (18.6) | 45 (20.5) | 22 (16.4) | 20 (16.7) | 14 (14.3) |
 5 | 18 (4.3) | 38 (6.5) | 26 (11.8) | 12 (9.0) | 10 (8.3) | 12 (12.2) |
  ≥ 6 | 33 (7.9) | 54 (9.2) | 38 (17.3) | 23 (17.2) | 21 (17.5) | 28 (28.6) |
Common baseline comorbid conditions, n (%)a | ||||||
 Insomnia | 64 (15.4) | 132 (22.5) | 65 (29.5) | 49 (36.6) | 42 (35.0) | 27 (27.6) |
 Allergies | 63 (15.1) | 95 (16.2) | 38 (17.3) | 30 (22.4) | 24 (20.0) | 19 (19.4) |
 Neck pain | 60 (14.4) | 95 (16.2) | 51 (23.2) | 26 (19.4) | 29 (24.2) | 28 (28.6) |
 Hypertension | 61 (14.7) | 82 (14.0) | 32 (14.5) | 26 (19.4) | 22 (18.3) | 18 (18.4) |
 Back pain | 46 (11.1) | 92 (15.7) | 35 (15.9) | 20 (14.9) | 24 (20.0) | 20 (20.4) |
 Obesity | 47 (11.3) | 90 (15.3) | 38 (17.3) | 37 (27.6) | 27 (22.5) | 20 (20.4) |
 MDD | 41 (9.9) | 93 (15.8) | 47 (21.4) | 134 (100.0) | 39 (32.5) | 22 (22.4) |
 GAD | 27 (6.5) | 93 (15.8) | 52 (23.6) | 39 (29.1) | 120 (100.0) | 22 (22.4) |
 Chronic pain | 32 (7.7) | 79 (13.5) | 41 (18.6) | 26 (19.4) | 34 (28.3) | 22 (22.4) |
 Asthma | 38 (9.1) | 63 (10.7) | 33 (15.0) | 18 (13.4) | 20 (16.7) | 13 (13.3) |
Clinician-estimated adherence rate, mean (SD) | 92.3 (17.6) | 95.1 (13.1) | 89.8 (19.7) | 95.0 (12.3) | 95.6 (10.0) | 95.0 (11.2) |
Patients with ≥ 80% adherence, n (%) | 362 (87.0) | 550 (93.7) | 182 (82.7) | 125 (93.3) | 114 (95.0) | 90 (91.8) |
Discontinuation rate after fremanezumab index dose, n (%) | 31 (7.5) | 47 (8.0) | 17 (7.7) | 5 (3.7) | 14 (11.7) | 12 (12.2) |